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Abstract We analyzed changes of intracellular RNA level in
breast cancer cells using BT-20, BT-474, and MCF-7 cell
lines. It is the continuation of our former studying the effect
of bacterial ribonucleases on physiological and biochemical
parameters of breast cancer cells. For the first time, we tested
ability ofBacillus pumilusRNase (binase) to effect the level of
intracellular RNA in these cells. Differences in total RNA
level under of the binase action on the cells of triple negative,
triple positive, and double positive breast cancer during 48 h
of treatment were not detected. The sensitivity of cells to
binase was not associated with a reduction of the intracellular
RNA level.
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1 Introduction
Breast cancer is a socially significant cancer in females world-
wide. The possibilities of breast cancer treatment are primarily
determined by the biological characteristics of the tumor.
Breast cancer has several sub-types: one of these sub-types
is known as triple negative breast cancer (TNBC). TNBC does
not grow in response to the hormones estrogen, progesterone,
or HER2/neu [1]. Therefore, TNBC does not respond to hor-
monal therapies that target the receptors of these hormones.
For this type of breast cancer, targeted treatments are not
available as for other sub-types of breast cancer. Thus, patients
with hormone-sensitive tumors and with triple negative tu-
mors differ in their susceptibility to therapy. Approximately
10–20% of breast cancers are triple negative [2].
Cytotoxic ribonucleases of various organisms were known
to be used as potential antitumor agents. The commercial
preparation of RNase from the frog Rana pipiens oocytes
(onconase) is now at the third stage of clinical trials as a drug
against lung mesothelioma [3]. Antitumor activity was found
to be characteristic of RNase from bovine testes (BS-RNase),
RNases of human eosinophilic granules, and of a number of
RNases of lower organisms, including fungi, actinomycetes,
and bacteria [4]. Binase is an enzyme that has been isolated
from a bacterium Bacillus pumilus. We have shown previous-
ly that it has selective antitumor properties for different types
of malignant tumors [5, 6], include breast cancer tumors [7].
The aspects of enzyme action toward cells of the immune
system [8] and non-malignant cells [9] have also been
described.
Here, we demonstrate for the first time that sensitivity of
breast cancer cells to binase, include triple negative, does not
depend on cellular RNA catalytic degradation.
2 Materials and Methods
Bacterial guanyl-specific RNAse from soil bacterium Bacillus
pumilus, binase (12.2 kDa, 109 amino acid residues, pI 9.5),
was homogenously isolated from culture liquid of Escherichia
coli BL21 carrying the pGEMGX1/ent/Bi plasmid, according
to Schulga et al. [10].
Cell cultures of breast cancer cell lines BT-20 (triple nega-
tive), BT-474 (triple positive), and MCF-7 (double positive)
were obtained from all-Russian cell culture collection. Cells
were cultivated in RPMI supplementedwith penicillin (100U/
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